Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases

Zhe-Sheng Chen1, Amit K Tiwari

  • 1Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439, USA. chenz@stjohns.edu

The FEBS Journal
|July 12, 2011
PubMed

Insights

Multidrug resistance proteins (MRPs) 1-9, part of the ABCC subfamily, are crucial for extruding chemotherapy drugs from cancer cells. Mutations in these transporters are linked to cancer treatment failure and genetic disorders.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • ATP-binding cassette (ABC) transporters are membrane proteins facilitating substance transport via ATP hydrolysis.
  • The ABCC subfamily includes nine multidrug resistance proteins (MRPs) 1-9, vital in cellular efflux.
  • MRPs influence drug disposition, elimination, and transport of endogenous organic anions.

Purpose of the Study:

  • To summarize current knowledge on MRP1-MRP9.
  • To review the role of MRPs in cancer chemotherapy and human genetic diseases.
  • To discuss specific MRP mutations linked to Dubin-Johnson syndrome and Pseudoxanthoma elasticum.

Main Methods:

  • Literature review of biochemical and physiological data.
  • Analysis of studies on MRP function in cancer cells.
  • Examination of genetic studies linking MRP mutations to human disorders.

Main Results:

  • MRPs 1-9 mediate the efflux of chemotherapeutic agents, contributing to multidrug resistance in tumors.
  • MRPs play roles in drug disposition in normal tissues and elimination via hepatobiliary/renal pathways.
  • Mutations in MRP2/ABCC2 cause Dubin-Johnson syndrome, and MRP6/ABCC6 mutations cause Pseudoxanthoma elasticum.

Conclusions:

  • MRPs are critical targets in cancer chemotherapy due to their role in drug resistance.
  • Dysfunctional MRPs are implicated in significant human genetic disorders.
  • Further research into MRPs can inform therapeutic strategies and genetic disease understanding.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...